Song Jinfang, Xu Yi, Xu Liu, Yang Tingting, Chen Ya, Ying Changjiang, Lu Qian, Wang Tao, Yin Xiaoxing
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, No.209, Tongshan Road, Xuzhou, China.
Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China.
BMC Endocr Disord. 2025 Jun 5;25(1):138. doi: 10.1186/s12902-025-01960-x.
The role of genetic susceptibility in early warning and precise treatment of diabetic kidney disease (DKD) requires further investigation. A case-control study was conducted to evaluate the predictive effect of GSK3B genetic polymorphisms on the susceptibility to DKD, with the aim of providing a theoretical basis and laboratory rationale for the prediction of the risk of developing DKD in patients with type 2 diabetes mellitus (T2DM). The GSK3B genotyping was performed by SNaPshot method based on Genotype-Tissue Expression database and thousand genomes database to screen tag SNPs. The polymorphisms of GSK3B tag SNPs were statistically analyzed for their effects on DKD susceptibility and clinical indicators. Urinary exosomes from DKD patients were extracted, protein expression levels of GSK3β were detected by ELISA kits, and kinase activity of GSK3β was quantified by kinase activity spectrometry to evaluate the correlation between the gene polymorphisms of GSK3B and the expression levels and activities of GSK3β. A machine learning model was constructed for assessing the efficacy of GSK3B polymorphisms in predicting the risk of developing DKD in patients with T2DM. A total of 800 subjects who met the inclusion and exclusion criteria were included in the case-control study, including 200 healthy control subjects, 300 patients with T2DM and 300 patients with DKD. Genetic analysis identified five tag SNPs (rs60393216, rs3732361, rs2199503, rs1488766, and rs59669360) associated with the susceptibility to DKD. The protein level and activity of GSK3β were significantly elevated in DKD patients. On the other hand, the expression levels and kinase activity of GSK3β in exosomes differed significantly between patients with different genotypes of the GSK3B, suggesting that the effect of GSK3B gene polymorphisms on GSK3β expression and activity may be an important mechanism leading to individual differences in susceptibility to DKD. XG Boost algorithm model identified rs60393216 and rs1488766 as important biomarkers for clinical early warning of DKD.
基因易感性在糖尿病肾病(DKD)早期预警和精准治疗中的作用尚需进一步研究。开展了一项病例对照研究,以评估GSK3B基因多态性对DKD易感性的预测作用,旨在为预测2型糖尿病(T2DM)患者发生DKD的风险提供理论依据和实验室依据。基于基因型-组织表达数据库和千人基因组数据库,采用SNaPshot方法进行GSK3B基因分型,以筛选标签单核苷酸多态性(tag SNPs)。对GSK3B标签SNPs的多态性进行统计学分析,以研究其对DKD易感性和临床指标的影响。提取DKD患者的尿外泌体,采用酶联免疫吸附测定试剂盒检测GSK3β的蛋白表达水平,并用激酶活性光谱法对GSK3β的激酶活性进行定量,以评估GSK3B基因多态性与GSK3β表达水平及活性之间的相关性。构建机器学习模型,以评估GSK3B基因多态性对预测T2DM患者发生DKD风险的有效性。该病例对照研究共纳入800名符合纳入和排除标准的受试者,包括200名健康对照者、300名T2DM患者和300名DKD患者。基因分析确定了5个与DKD易感性相关的标签SNPs(rs60393216、rs3732361、rs2199503、rs1488766和rs59669360)。DKD患者中GSK3β的蛋白水平和活性显著升高。另一方面,不同GSK3B基因型患者外泌体中GSK3β的表达水平和激酶活性存在显著差异,这表明GSK3B基因多态性对GSK3β表达和活性的影响可能是导致DKD易感性个体差异的重要机制。XG Boost算法模型确定rs60393216和rs1488766为DKD临床早期预警的重要生物标志物。